Aim: It has been seen that two third of patient who were having elevated blood pressure also unaware regarding their condition and as a result develop further complication. In a state like Bihar there was a need to correlate with a blood biomarkers which shed light on the underlying processes involved in the onset, development, and progression of essential hypertension. To analyse the potentiality of Serum uric acid to use as a biomarker to detect essential Hypertension Severity

Material: This was a single centre study. Total 120 patients were included in this trial where 60 subjects were with essential hypertension and rest 60 patients were without essential hypertension. This study was conducted at Diabetes centre in Bihar. Blood pressure was measured by a sphygmomanometer (Brand name Diamond) and pathological blood test was conducted at single NABL accredited pathology laboratory. Consent was taken from each participant. Current study was performed in accordance with the declaration of Helsinki.

Result: Subjects with essential hypertension also having high mean serum uric acid of 6.8±.2 mg/dl where as it was normal i.e. 4.2±0.2 mg/dl with control subjects who were not having any grade of hypertension (p≤0.005). It was observed that even duration of HTN is effect the level of serum uric acid. Subjects who were having HTN for more than 5 years were having serum uric acid of 7.1±0.3 mg/dl whereas subjects who were having HTN for less than 5 years were having serum uric acid of 4.5±0.2 mg/dl.

Conclusion: Serum uric acid can be used as a biomarker to detect essential hypertension severity and duration.

Keywords: Hypertension, uric acid, biomarker, severity and duration.

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224–2260.
2. Leeder S, Raymond S, Greenberg H, Liu H. A race against time. The challenge of cardiovascular disease in developing economies. New York:Columbia University; 2004
3. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366:1744–1749.
4. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18:73–78.
5. Mackay J, Mensah G. Atlas of heart disease and stroke. Geneva:World Health Organization; 2004.
6. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217–223
7. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS 2010;5:463-6.
8. Dhawan V, Sharma I, Mahajan N, et al. Implication of Endothelin-2 and Oxidative Stress Biomarkers in Essential Hypertension. J Hypertension 2014;3: 1095-2167.
9. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-97.
10. Lüders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008;26:1487-96.
11. Kinsey D, Walther R, Sise HS, Whitelaw G, Smithwick R: Incidence of hyperuricemia in 400 hypertensive subjects. Circulation 1961; 24: 972–973.
12. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona young men atherosclerosis risk factors study. Int J Obesity Relat Metab Disord 1996; 20: 975-980.
13. Malinow MR, Levenson J, Giral P, Nieto FJ, Razavian M, Segond P, et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995; 114:175-183.
14. Woo J, Swaminathan R, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994; 70: 486-491.
15. Puig JG, Ruilope LM. “Uric acid as a cardiovascular risk factor in arterial hypertension.” Journal of Hypertension. 1999; 17:869–872.
16. McCord JM. “Oxygen-derived free radicals in postischemic tissue injury”. New England Journal of Medicine. 1985; 312:159–163.
17. Lacy F, O’Connor DT, Schmid-Schoenbein GW. “Elevation in plasma hydrogen peroxide in hypertensive and normotensive subjects at genetic risk for hypertension”. Journal of Hypertension. 1998; 16:292–303.
18. Takeda T, Kohno M. Brain natriuretic peptide in hypertension. Hypertens Res 1995;18:259-66.
19. Tanindi A, Cemri M. Troponin elevation in conditions other than acute coronary syndromes. Vasc Health Risk Manag 2011;7:597-603.
20. Currie G, Delles C. Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients. CurrHypertens Rep 2016;18:54.
21. A. Breckenridge “Hypertension and Hyperuricemia” The Lancet 1966: 287;15-18.

Dr Mritunjay Kumar

Assistant Professor, Department of Medicine, Narayan Medical College and Hospital, Sasaram, Bihar, India